[A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
نویسندگان
چکیده
A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate A. Taïeb a,∗, J. Constans b, F.-X. Mahon c a Service de dermatologie et dermatologie pédiatrique, centre de référence pour les maladies rares de la peau, Inserm U876, CHU de Bordeaux, université Victor-Segalen–Bordeaux-II, Bordeaux, France b Service de médecine vasculaire, CHU de Bordeaux, hôpital Saint-André, 1, rue Jean-Burguet, 33075 Bordeaux cedex, France c Service des maladies du sang, hôpital du Haut-Lévêque, Inserm U876, université Victor-Segalen–Bordeaux-II, Bordeaux, France
منابع مشابه
Molecular framework for response to imatinib mesylate in systemic sclerosis.
Systemic sclerosis (SSc) is an autoimmune disease in which the tyrosine kinases platelet-derived growth factor receptor (PDGFR) and Abl are hypothesized to contribute to the fibrosis and vasculopathy of the skin and internal organs. Herein we describe 2 patients with early diffuse cutaneous SSc (dcSSc) who experienced reductions in cutaneous sclerosis in response to therapy with the tyrosine ki...
متن کاملPlatelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases
Some systemic rheumatic diseases and disorders, especially fibrotic and vascular disorders, are often refractory to corticosteroid therapy. Recently, ever accumulating evidence suggests that platelet-derived growth factor (PDGF) is involved in those refractory diseases. Imatinib mesylate inhibits the activation of PDGF receptor as well as c-Abl, Bcr-Abl and c-Kit tyrosine kinases. It has theref...
متن کاملLocal delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth.
PURPOSE In an effort to develop new therapeutic strategies to treat malignant gliomas, we have designed poly (lactic-co-glycolic) acid (PLGA) microparticles that deliver imatinib mesylate, a small molecule tyrosine kinase inhibitor. The local continuous release of imatinib mesylate at the tumor site overcomes many obstacles associated with systemic delivery. EXPERIMENTAL DESIGN Polymeric micr...
متن کاملEffects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants.
Experimental autoimmune encephalomyelitis (EAE) is a mouse model for multiple sclerosis (MS), This autoimmune disease is mainly mediated by adaptive and innate immune responses that lead to an inflammatory demyelination and axonal damage. Imatinib mesylate is a selective protein tyrosine kinase inhibitor with immunomodulatory properties that abrogates multiple signal transduction pathways in im...
متن کاملEvaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML). We aimed to evaluate thyroid function at baseline and at 1, 3, 6 and 12 months after initiation of Imatinib mesylate therapy in 20 newly diagnosed BCR-ABL positive CML patients. Methods: This study was done during 2013-2014, 20 new c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- La Revue de medecine interne
دوره 29 3 شماره
صفحات -
تاریخ انتشار 2008